Talphera, Inc. (TLPH )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TLPH
- Company Talphera, Inc.
- Price $1.33
- Changes Percentage 6
- Change 0.075
- Day Low $1.26
- Day High $1.4
- Year High $1.45
- Year Low $0.38
- Market Cap $27,081,933
- Price Avg 50 EMA (D) $1.1
- Price Avg 200 EMA (D) $0.66
- Exchange NASDAQ
- Volume 588,126
- Average Volume 2,534,387
- Open $1.28
- Previous Close $1.25
- EPS -0.39
- PE -3.38
- Earnings Announcement 2025-11-12 21:00:00
- Shares Outstanding $20,516,616
Company brief: TALPHERA, INC. (TLPH )
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Mr. Vincent J. Angotti
- https://talphera.com
- US
- N/A
- 02-11-2011
- US00444T2096
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.